BioMarin Pharmaceuticals
BMRN
BMRN
546 hedge funds and large institutions have $18B invested in BioMarin Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 85 funds opening new positions, 177 increasing their positions, 207 reducing their positions, and 50 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
2.79% more ownership
Funds ownership: 96.44% → 99.23% (+2.8%)
0% more funds holding in top 10
Funds holding in top 10: 14 → 14 (0)
14% less repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 207
Holders
546
Holding in Top 10
14
Calls
$193M
Puts
$141M
Top Buyers
| 1 | +$421M | |
| 2 | +$265M | |
| 3 | +$177M | |
| 4 |
Morgan Stanley
New York
|
+$99M |
| 5 |
Millennium Management
New York
|
+$80M |
Top Sellers
| 1 | -$337M | |
| 2 | -$62.6M | |
| 3 | -$56.1M | |
| 4 |
Pictet Asset Management
Carouge,
Switzerland
|
-$44.7M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$44.1M |